XML 22 R15.htm IDEA: XBRL DOCUMENT
v3.21.4

RESEARCH AND DEVELOPMENT | 12 Months Ended
--- | ---
Sep. 30, 2021
Research And Development [Abstract] |
RESEARCH AND DEVELOPMENT [Text Block] | 10. RESEARCH AND DEVELOPMENT Research and development expense recognized in the consolidated statements of comprehensive loss is comprised of the following:
| Year ended | Year ended | Period ended
| September 30, 2021 | September 30, 2020 | September 30, 2019
| $ | $ | $
Laboratory costs (see Note 11) | 82,871 | 25,874 | 27,164
Novel drug development | 3,638,910 | 110,029 | -
Patents and related payments | 513,302 | 13,895 | -
Salary and subcontractors | 1,369,769 | 43,754 | 14,845
Share-based compensation (see Note 6) | 709,136 | 161,300 | -
| 6,313,988 | 354,852 | 42,009

X
- References No definition available. + Details
Name: | drug_ResearchAndDevelopmentAbstract
Namespace Prefix: | drug_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of research and development expense. [Refer: Research and development expense] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2020-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_10_e&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration